Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukaemia: results of the ITCC-059 study

Bookmark and Share
Published: 9 Dec 2020
Views: 111
Rating:
Save
Dr Erica Brivio - Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands

Dr Erica Brivio speaks to ecancer at virtual ASH 2020 about the results of the ITCC-059 study looking into inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukaemia.

She explains that the phase I study established that inotuzumab ozogamicin was well tolerated and provided the recommended dose for the phase II trial, which confirmed promising anti-leukaemic activity.

Dr Brivio reports that the overall response rate was 81% with 95% MRD negativity.